RT Journal Article
SR Electronic
T1 Exhaled aerosol increases with COVID-19 infection, and risk factors of disease symptom severity
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.09.30.20199828
DO 10.1101/2020.09.30.20199828
A1 David A. Edwards
A1 Dennis Ausiello
A1 Robert Langer
A1 Jonathan Salzman
A1 Tom Devlin
A1 Brandon J. Beddingfield
A1 Alyssa C. Fears
A1 Lara A. Doyle-Meyers
A1 Rachel K. Redmann
A1 Stephanie Z. Killeen
A1 Nicholas J. Maness
A1 Chad J. Roy
YR 2020
UL http://medrxiv.org/content/early/2020/10/02/2020.09.30.20199828.abstract
AB Coronavirus disease-19 (COVID-19) transmits by droplets generated from surfaces of airway mucus during processes of respiration within hosts infected by severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) virus. We studied respiratory droplet generation and exhalation in human and nonhuman primate subjects with and without COVID-19 infection to explore whether SARS-CoV-2 infection, and other changes in physiological state, translates into observable evolution of numbers and sizes of exhaled respiratory droplets in healthy and diseased subjects. In our observational cohort study of the exhaled breath particles of 74 healthy human subjects, and in our experimental infection study of eight nonhuman primates infected by aerosol with SARS-CoV-2, we found that exhaled aerosol particles increase one to three orders of magnitude with aging, high BMI, and COVID-19 infection. These variances appear to be related to changes in airway mucus surface composition and the propensity for mucus surfaces to breakup into small droplets during acts of breathing. We also observed that 20% of those participating in our human study accounted for 80% of the overall exhaled bioaerosol, reflecting a bioaerosol distribution analogous to a classical 20:80 super spreader distribution.Competing Interest StatementThe authors have declared no competing interest.Funding StatementFunding. The work at the Tulane National Primate Research Center was supported in part by the National Institute of Allergy and Infectious Disease (NIAID) Contract No. HHSN272201700033I (CJR) and also supported in part by grant OD011104 from the Office of Research Infrastructure Programs (ORIP), Office of the Director, NIH.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:An independent body (Ethical and Independent Review Services) has provided a letter stating "Using a Determination of Research with Human Subjects assessment process, the E&I administrative review team has reviewed your submission. We have determined that your project is "research" with "human subjects" but it is not regulated. No formal IRB review is required at this time. Please keep this determination document with your project records." The determination document number associated with review of this project as assigned by E&I Review Services is 20167-01. A PDF fo the letter from this entity is avialable for upload if needed. All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData and Materials Availability. All data from this study are presented in the article and Supplementary Materials.